AstraZeneca agrees to divest Viela shareholding
1 February 2021 12:15 GMT AstraZeneca agrees to divest Viela shareholding AstraZeneca has agreed, subject to certain limited exceptions, to divest its 26.7% ownership in Viela Bio, Inc. (Viela), as part of the proposed acquisition of Viela by Horizon Therapeutics plc (Nasdaq: HZNP). AstraZeneca is anticipating to receive cash proceeds and profit of c.$760-$780m upon closing for the sale of the holding, which will be recorded in Reported and Core Other Operating Income and Expense in the Company's financial statements. The divestment is expected to complete by the end of the first